A model to estimate the probability of hepatitis B- and Haemophilus influenzae type b-vaccine uptake into national vaccination programs

Vaccine

Volumn 18, Issue 21, 2000, Pages 2223-2230

  Miller, Mark A ^a   Flanders, W Dana ^b  

^a Children's Vaccine Initiative   (Switzerland)

^b EMORY UNIVERSITY   (United States)

Author keywords

Economics; Haemophilus influenzae type b; Hepatitis B; Vaccines

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE;

ARTICLE; DRUG COST; HEALTH CARE POLICY; HEALTH PROGRAM; PRIORITY JOURNAL; PROBABILITY; SOCIOECONOMICS; STATISTICAL MODEL; VACCINATION;

HAEMOPHILUS VACCINES; HEPATITIS B VACCINES; HUMANS; LOGISTIC MODELS; MODELS, STATISTICAL; POLYSACCHARIDES, BACTERIAL; PROBABILITY; VACCINATION;

EID: 0034008898     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(99)00563-0     Document Type: Article

References (11)

1. State of the world's vaccines and immunization. 1996;World Health Organization, Geneva.
2. World Health Assembly. Immunization and vaccine quality. Forty-fifth World Health Assembly, Geneva 4-14 May 1992. 1992;. Resolution WHA45.17.
3. The WHO position paper on Haemophilus influenzae type b conjugate vaccines. Weekly Epidemiological Record. 73:1998;64-68.
4. Miller M, McCann L. Policy analysis of the use of hepatitis b, Haemophilus influenzae type b-, Streptococcus pneumoniae-conjugate and rotavirus vaccines in national immunization schedules. Health Economics 2000 (in press).
5. World Population Prospects The 1996 revision. 1997;United Nations Publications, New York.
6. World Bank. World Development Report 1997: the State in a changing world. 1997;World Bank, Washington DC.
7. World Bank. World Development Report 1993: investing in health. 1993;Oxford University Press, New York.
8. Colton T. Statistics in Medicine. 1974;221-223 Little Brown and Company, Boston.
9. Lemeshow S., LeGall S.R. Modeling the severity of illness of ICU patients: a systems update. JAMA. 272:1994;1049-1055.
10. Mercer Management Consulting. Report on the United States vaccine industry. 1995;Children's Vaccine Initiative, Geneva.
11. Batson A. Win-win interactions between the public and private sectors. Nature Medicine. 4:1998;487-491.